Precigen (PGEN) Preferred Stock Liabilities (2012 - 2013)

Precigen's (PGEN) quarterly Preferred Stock Liabilities came in at $35.2 million in Q2 2013, up 2490.15% on a QoQ basis from $1.4 million in Q4 2012.

Precigen (PGEN) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends

Precigen (PGEN) has 2 years of Preferred Stock Liabilities data on file, last reported at $35.2 million in Q2 2013.

On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $35.2 million in Q2 2013; TTM through Jun 2013 was $35.2 million, a N/A change from a year earlier, with the FY2012 full-year figure at $1.4 million, down 95.16% from the prior year.
Preferred Stock Liabilities for Q2 2013 stood at $35.2 million, up from $1.4 million in the prior quarter.
Over the last five years, Preferred Stock Liabilities for PGEN reached as high as $35.2 million in Q2 2013 and fell as low as $1.4 million in Q4 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Precigen	1.96 Bn	1.96 Bn	20.69 Mn	-

Download Data

Date	Value
Jun 30, 2013	35.23 Mn
Dec 31, 2012	1.36 Mn